retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Explained: The Changing Medicine Triple hormone receptor agonist retatrutide

The glucagon receptor arm is the part of the design that sets Retatrutide apart, since it appears to add energy expenditure rather than relying on appetite suppression alone

1 More recently, additional pathophysiologic mechanisms have been identified that are implicated in contributing to impaired glucose homeostasis and the varied metabolic alterations associated with T2DM

Severe gastrointestinal reactions can precipitate acute kidney injury

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z

Schn, E

Dosing starts at 0.75 mg once a week for at least four weeks